TIGIT Antibody / T cell immunoglobulin and ITIM domain protein, 20ug

Immune checkpoint TIGIT antibody targets T-cell immunoreceptor with Ig and ITIM domains, an inhibitory surface receptor encoded by the TIGIT gene that plays a central role in restraining immune activation. TIGIT is expressed on multiple immune cell subsets, including activated effector T cells, regulatory T cells, and natural killer cells, where it functions as a negative regulator of immune responses. As part of the immune checkpoint network, TIGIT helps balance immune activation and tolerance under physiological and pathological conditions.<br><br>TIGIT exerts its inhibitory function through engagement with ligands of the poliovirus receptor family, most notably CD155 and CD112, which are expressed on antigen-presenting cells, endothelial cells, and many tumor cells. Ligand binding favors inhibitory signaling through the TIGIT cytoplasmic ITIM domain, resulting in suppression of T-cell receptor signaling, reduced cytokine production, and diminished cytotoxic activity. Immune checkpoint TIGIT antibody detection is therefore useful for examining immune suppression mechanisms in complex tissue environments.<br><br>In addition to direct signaling effects, TIGIT influences immune responses by shaping the cellular microenvironment. TIGIT engagement can promote immunosuppressive phenotypes in antigen-presenting cells and reinforce regulatory signaling circuits that limit effector immune activity. These effects contribute to immune adaptation during chronic antigen exposure and play an important role in maintaining immune homeostasis during prolonged inflammatory stimulation.<br><br>Pathologically, elevated TIGIT expression is a hallmark of immune exhaustion and is frequently observed in tumor-infiltrating lymphocytes and chronically stimulated immune cells. High TIGIT levels are associated with impaired antitumor immunity and reduced immune-mediated clearance, making TIGIT a focal point in immuno-oncology research. Dysregulated TIGIT signaling has also been implicated in chronic infection and autoimmune disease, where inappropriate immune inhibition or activation contributes to disease progression.<br><br>Clone TIGIT/3034 is designed to recognize immune checkpoint TIGIT in research applications. Immune checkpoint TIGIT antibody reagents are suitable for detecting checkpoint receptor expression in immune cells and tissue samples, supporting studies focused on immune exhaustion, checkpoint pathway regulation, and disease-associated immune suppression.<br><br>For broader analysis of TIGIT as an immune checkpoint marker across applications, see our <a href=../tds/tigit-antibody-vstm3-vsig9-tigit3017-v7583>TIGIT antibody TIGIT/3017</a>.

Specifications